The protective effects of neutrophil elastase inhibitor on organ dysfunction after hepatectomy

The protective effects of neutrophil elastase inhibitor on organ dysfunction after hepatectomy - neutrophil elastase inhibitor and hepatectomy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004770

Enrollment

Registered

2011-01-01

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma, metastatic liver cancer, cholangiocarcinoma

Interventions

group of administration of neutrophil elastase inhibitor non-administration group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with liver tumor who takes hepatectomy

Exclusion criteria

Exclusion criteria: onset of adverse effects of drug

Design outcomes

Primary

Measure	Time frame
improvement of liver dysfunction after hepatectomy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026